胞质分裂
癌症研究
基因敲除
中段
肺癌
生物
细胞生物学
下调和上调
泛素
调节器
免疫
小型GTPase
免疫系统
信号转导
CD8型
吞噬体
癌细胞
免疫检查点
细胞生长
激酶
细胞周期
细胞
获得性免疫系统
细胞周期蛋白依赖激酶1
细胞周期检查点
泛素连接酶
癌症
PLK1
靶向治疗
作者
Shuaihu Li,Longfu Zhang,Tian Xu,Yan Shang,Xinlei Cai,Jian Zhang,Yunjian Pan,Chongyang Li,Lin Wang,Dongxian Jiang,Kan Huang,Xi Dai,SHUHAN LYU,Bing Hu,朱宏文,Hu Zhou,B. K.W. NG,Fuming Li,Yingyong Hou,Hongbin Ji
标识
DOI:10.1038/s41419-026-09279-8
摘要
Abstract Lung cancer remains the leading cause of cancer-related mortality worldwide, highlighting the critical need to identify key oncogenic drivers and develop effective therapeutic strategies. Here, we demonstrate that pre-mRNA processing factor 19 (PRPF19) is significantly upregulated in lung cancer tissues and correlates with poor clinical prognosis. Mechanistically, PRPF19 mediates linear (M1-linked) ubiquitylation of Citron Kinase (CIT), which is essential for CIT midbody localization and successful cytokinesis; PRPF19 knockdown induces cytokinesis failure, cell cycle arrest, and impaired proliferation. In parallel, PRPF19 promotes lysosomal degradation of p65 via linear ubiquitylation, thereby suppressing NF-κB signaling and CXCL10 expression. PRPF19 knockdown stabilizes p65, elevates CXCL10, and enhances CD8 + T cell infiltration and anti-tumor immunity in a CXCL10/CXCR3-dependent manner. Collectively, our findings establish PRPF19 as a dual function regulator governing both cytokinesis and immune evasion in lung cancer, revealing a promising therapeutic target and providing mechanistic basis for novel treatment strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI